Rectal Cancer
A randomized, open-label, 3-arm Phase 3 study of precemtabart tocentecan with or without bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03)
- Details
ClinicalTrials.gov ID:
NCT07549412
Diagnosis Type:
NA
USOR Number:
- Address
,
P: